China Resources Double-Crane Pharmaceutical Co.,Ltd. China Resources Double-Crane Pharmaceutical Co.,Ltd.

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

Rank in Stocks #5375
China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its... China Resources Double-Crane Pharmaceutical Co.,Ltd., together with its affiliated companies, operates as a prominent pharmaceutical enterprise within the People's Republic of China. The company's diverse product range includes various types of infusion solutions, available in soft bags, plastic and glass bottles, as well as inner-sealed and blend polypropylene bags. Its manufacturing capabilities extend to numerous injectable products, such as levofloxacin methylate, ambroxol hydrochloride glucose, fructose, invert sugar, hydroxyethyl starch, and sodium chloride injections, among others. Additionally, it supplies vital dialysate solutions for both peritoneal and hemodialysis. A substantial part of its portfolio is dedicated to addressing cardiovascular and cerebrovascular diseases, featuring medications like compound reserpine triamterene tablets, pitavastatin calcium tablets, telmisartan capsules, suppository capsules, banidipine hydrochloric acid sustained-release capsules, and edaravone. Furthermore, China Resources Double-Crane offers treatments for endocrinological conditions and a selection of pediatric drugs, notably including pediatric compound amino acid injections. The company's offerings also encompass nutritional supplements, such as vitamins E and C, and a variety of anti-infective pharmaceuticals. Headquartered in Beijing, the People's Republic of China, China Resources Double-Crane Pharmaceutical Co.,Ltd. is an affiliate of Beijing Pharmaceutical Group Co., Ltd.
Share Price
$2.28
Last synced: 2026-11-13
Market Cap
$2.36B
Change (1 day)
-0.79%
Change (1 year)
-14.78%
Country

Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this

Trade China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)

Category

Healthcare
EPS for China Resources Double-Crane Pharmaceutical Co.,Ltd. (600062)
EPS as of September 2026 TTM: $0.23
According to China Resources Double-Crane Pharmaceutical Co.,Ltd.'s latest financial reports, its current EPS (TTM) is $0.23. At the end of 2025 the company had an EPS of $0.23, an increase over its 2024 EPS of $0.22.
EPS history for China Resources Double-Crane Pharmaceutical Co.,Ltd. from 2000 to 2026
EPS at the end of each year
Year EPS Change
2026 (TTM) $0.23 -0.96%
2025 $0.23 4.99%
2024 $0.22 -5.99%
2023 $0.23 39.32%
2022 $0.17 16.74%
2021 $0.14 -3.67%
2020 $0.15 1.38%
2019 $0.15 7.25%
2018 $0.14 8.59%
2017 $0.12 27.17%
2016 $0.10 0.93%
2015 $0.10 -15.36%
2014 $0.11 -34.44%
2013 $0.17 45.30%
2012 $0.12 18.52%
2011 $0.10 6.39%
2010 $0.10 18.36%
2009 $0.08 15.97%
2008 $0.07 -11.58%
2007 $0.08 178.72%
2006 $0.03 -6.62%
2005 $0.03 4,214.29%
2004 0.00 -93.00%
2003 $0.01 -62.41%
2002 $0.03 9.92%
2001 $0.02 25.39%
2000 $0.02 0.00%
EPS for similar companies or competitors
Company EPS EPS Difference Country
$6.03 2,547.01%
DE
$6.01 2,537.31%
DE
$1.53 572.91%
JP
$3.66 1,506.67%
CH
$0.45 97.54%
IL

Questions about China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS)

What is China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS)?

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) over the last twelve months is $0.23, as of Sep 2026.

What was China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) in 2025?

In 2025, China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) was $0.23, 4.55% more than in 2024 ($0.22).

How has China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) changed since 2020?

From 2020 to 2025, China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) went from $0.15 to $0.23, an average growth of 8.92% a year.

How does China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) compare with similar companies?

China Resources Double-Crane Pharmaceutical Co.,Ltd.'s earnings per share (EPS) ($0.23) is lower than that of all 5 similar companies listed above. The highest among them is MERCK Kommanditgesellschaft auf Aktien, with $6.03.